<DOC>
	<DOCNO>NCT00006223</DOCNO>
	<brief_summary>RATIONALE : Drugs flt3L may stimulate person 's immune system help kill cancer cell . It yet know flt3L effective treat acute myeloid leukemia . PURPOSE : Randomized phase III trial determine effectiveness flt3L treat patient acute myeloid leukemia remission .</brief_summary>
	<brief_title>flt3L Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare failure-free survival overall survival patient acute myeloid leukemia complete remission treat maintenance flt3 ligand vs observation alone . - Compare long-term immunologic effect regimens patient . - Compare long-term safety toxicity regimens patient . OUTLINE : This randomize study . Patients stratify accord complete remission ( CR ) ( first v second vs third subsequent ) post-remission therapy ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive flt3 ligand subcutaneously daily day 1-14 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation alone . Patients begin treatment observation within 4 week documentation CR induction therapy within 4 week discharge hospital post-remission therapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 139 patient accrue study within approximately 28 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Flt3 ligand protein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia first , second , third , subsequent complete remission ( CR ) Must least 60 year age first CR Must histological proof ( bone marrow aspirate , smear , touch prep marrow biopsy ) one follow prior achieve CR : Acute myeloblastic leukemia ( M0 , M1 , M2 ) Acute promyelocytic leukemia ( M3 ) Acute myelomonocytic leukemia ( M4 ) Acute monocytic leukemia ( M5 ) Acute erythroleukemia ( M6 ) Acute megakaryocytic leukemia ( M7 ) Refractory anemia excess blast transformation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 time upper limit normal ( ULN ) SGOT le 3 time ULN Renal : Creatinine le 2 mg/dL Cardiovascular : No clinically significant active cardiac disease Pulmonary : No clinically significant active pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled active autoimmune disease PRIOR CONCURRENT THERAPY : Biologic therapy : Prior autologous bone marrow transplantation ( BMT ) allow No prior allogeneic BMT Other prior immunotherapy allow received recent treatment Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>